Form 4: Iteos Therapeutics CFO Matthew Gall Receives Stock Options and Restricted Stock Units

Matthew Gall, CFO of Iteos Therapeutics, was granted stock options and restricted stock units (RSUs) on March 7, 2025, according to a Form 4 filing with the SEC.

Summary

• On March 7, 2025, Matthew Gall, the Chief Financial Officer of Iteos Therapeutics, Inc., received 24,000 restricted stock units (RSUs) and options to purchase 145,000 shares of common stock.
• The RSUs vest over four years, with 25% vesting on March 7, 2026, and the remainder vesting equally on an annual basis over the subsequent three years, contingent upon continued service.
• The stock options, with an exercise price of $7.05, also vest over four years, with 25% vesting on March 7, 2026, and the rest vesting in equal monthly installments over the following 36 months, subject to continued service.
• Following these transactions, Gall directly owns 89,429 shares of common stock and options to purchase 145,000 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of stock options and RSUs is a standard practice and suggests confidence in the company's future, but it's not a major event.

Positives

• The grant of RSUs and stock options to the CFO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.
• The vesting schedules of both the RSUs and stock options encourage long-term commitment from the CFO.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedules suggest an expectation of continued service from the CFO.

Industry Context

Stock option and RSU grants are common compensation practices for executives in the biotechnology industry, aligning their interests with shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Regeneron also use stock options and RSUs to incentivize their executives.
• The vesting schedule of four years with a one-year cliff (25% vesting after one year) is a typical vesting arrangement.

Stakeholder Impact

• Shareholders may view the grant of stock options and RSUs positively, as it aligns management's interests with theirs.
• Employees may see this as a sign of the company's commitment to its leadership.

Key Dates